Topica Pharmaceuticals, a privately held biotechnology company, has raised $27 million in a series B round of venture capital financing. The investment round was led by Third Rock Ventures and existing investors Prospect Venture Partners and Yasuda Enterprise Development Corp.
The company intends to use the proceeds to advance the company’s broad-spectrum agent for treatment of fungal infections of the nail. As part of the investment, Charles Homcy, managing director, venture partner at Third Rock, will join Topica’s board of directors.
Click here for the release from Market Wire.